Nonalcoholic Steatohepatitis (NASH) Market by Therapeutics | 2020

More documents

Recommendations

Info

Introductionof Nonalcoholic Steatohepatitis (NASH) Market The global market is expected to garner $1.6 billion by 2020, registering a CAGR of 25.6% during the period 2014-2020. The high prevalence of Type II diabetes and obesity, which lead to NASH and other nonalcoholic fatty liver diseases (NAFLD), would boost market growth. North America's heightened focus of NASH research has resulted in its accounting for nearly half of the global market. It is also the region with the maximum occurrences of NASH and other nonalcoholic fatty liver diseases. Europe ranks second in terms of the prevalence of NASH. The number of patients living with the diabetes worldwide is expected to soar from 371 million in 2012 to 552 million by 2030. This suggests that by 2030, there will be 3 new cases of diabetes every 10 seconds. "The rampant growth of diabetes and obesity has prompted pharmaceutical manufacturers to seek out novel pharmaceutical solutions to tap promising potential in NASH," states AMR analyst Roshan Deshmukh. "Instrumental initiatives and increasing clinical trials for the development of novel NASH therapeutics will steer its faster commercialization," adds the analyst.
Introductionof Nonalcoholic Steatohepatitis (NASH) Market Scope of the Report Key Benefits Key Audiences
Page 1: Nonalcoholic Steatohepatitis (NASH)
Page 5 and 6: Table of Content (TOC) Chapter 1: I
Page 7 and 8: Segments Nonalcoholic Steatohepatit
Page 9: Thank You Ceramic Matrix Composites

Nonalcoholic Steatohepatitis (NASH) Market by Therapeutics | 2020

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?